376 related articles for article (PubMed ID: 3888708)
1. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
Serup J; Holm P
Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
[TBL] [Abstract][Full Text] [Related]
2. The treatment of psoriasis with 0.1% domoprednate (a D-homocorticosteroid) and 0.1% betamethasone valerate ointment. A double-blind, randomized trial.
Christiansen JV; Foged E; Holm P; Jørgensen AS; Reymann F
Dermatologica; 1985; 170(4):195-8. PubMed ID: 3888709
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effect of topical corticosteroids on blood flow in human cutaneous tissue.
Kristensen JK; Wadskov S; Henriksen O
Acta Derm Venereol; 1978; 58(2):145-8. PubMed ID: 76394
[TBL] [Abstract][Full Text] [Related]
4. [Hydrocortisone butyrate (Locoid) compared with betamethasone valerate. A controlled clinical trail].
Thormann J
Ugeskr Laeger; 1976 Jan; 138(4):214-6. PubMed ID: 766347
[No Abstract] [Full Text] [Related]
5. [Systemic effects of topically applied hydrocortisone 17-butyrate 21-propionate ointment--comparative studies with betamethasone 17-valerate and hydrocortisone 17-butyrate ointment (author's transl)].
Takeda K
Nihon Hifuka Gakkai Zasshi; 1982 Mar; 92(4):503-13. PubMed ID: 7050471
[No Abstract] [Full Text] [Related]
6. [Assessment of value and risks of external treatment with clobetasol-17-propionate (Dermovate)].
van der Harst LC; Smeenk G; Burger PM; van der Rhee HJ; Polano MK
Ned Tijdschr Geneeskd; 1978 Feb; 122(7):219-23. PubMed ID: 345134
[No Abstract] [Full Text] [Related]
7. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
Korting HC; Vieluf D; Kerscher M
Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
[TBL] [Abstract][Full Text] [Related]
8. Comparison of betamethasone dipropionate (0.05%) and betamethasone valerate (0.1%) ointments in psoriasis and other dermatoses--a multicentric double-blind clinical study.
Sharma SD
Indian J Dermatol; 1986; 31(2-3):34-7. PubMed ID: 3327820
[No Abstract] [Full Text] [Related]
9. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroid-induced cutaneous atrophy and telangiectasia. Experimental production associated with weight loss in rats.
Smith JG; Wehr RF; Chalker DK
Arch Dermatol; 1976 Aug; 112(8):1115-7. PubMed ID: 952530
[TBL] [Abstract][Full Text] [Related]
11. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial.
Vena GA; Cassano N; D'Argento V; Milani M
Br J Dermatol; 2006 Feb; 154(2):353-6. PubMed ID: 16433809
[TBL] [Abstract][Full Text] [Related]
12. [Comparative double-blind study of a 0.1% hydrocortisone-17-butyrate cream (Locoid) and a 0.1% betamethasone-17-valerate cream (Betnovate) in patients with noninfected eczema].
von Fischer F
Ther Umsch; 1984 Jun; 41(6):429-32. PubMed ID: 6379975
[No Abstract] [Full Text] [Related]
13. Comparative toxicity study of hydrocortisone 17-butyrate 21-propionate (HBP) ointment and other topical corticosteroids in rats.
Kimura M; Tarumoto Y; Nakane S; Otomo S
Drugs Exp Clin Res; 1986; 12(8):643-52. PubMed ID: 3757761
[TBL] [Abstract][Full Text] [Related]
14. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
[TBL] [Abstract][Full Text] [Related]
15. Assessment of atrophy of human skin caused by corticosteroids using chamber occlusion and suction blister techniques.
Somerma S; Lassus A; Salde L
Acta Derm Venereol; 1984; 64(1):41-5. PubMed ID: 6203280
[TBL] [Abstract][Full Text] [Related]
16. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
Meyer E; Smith EW; Haigh JM; Kanfer I
Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
18. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis.
Xhauflaire-Uhoda E; Thirion L; Piérard-Franchimont C; Piérard GE
Dermatology; 2007; 214(4):328-32. PubMed ID: 17460405
[TBL] [Abstract][Full Text] [Related]
19. Topical corticosteroids in seborrhoeic dermatitis. A report from The General Practitioner Research Group.
Practitioner; 1982 Jun; 226(1368):1178-9. PubMed ID: 6213951
[No Abstract] [Full Text] [Related]
20. [Contact dermatitis caused by creams containing clobetasol propionate].
Camarasa JG; Serra-Baldrich E
Med Cutan Ibero Lat Am; 1988; 16(4):328-30. PubMed ID: 3068444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]